Navigation Links
Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
Date:3/27/2008

hat forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.

MODIGENE CONTACT: MEDIA CONTACT:

Shai Novik, President Barbara Lindheim

Modigene Inc. GendeLLindheim BioCom Partners

Tel: +1 866 644-7811 +1 212 918-4650

Email:

SOURCE Modigene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Modigene to Present at the Roth 2007 New York Investor Conference
3. GeneNews announces 2007 year end results
4. China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results
5. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY
9. Boston Scientific Announces Schedule for ACC 2008
10. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Aug. 14 Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... the second quarter of 2008 was $120,184 compared to,$202,127 ... from the sale,of PCT products and services was $117,698 ... to $136,355 for the prior year period. During the,second ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
... TROY, Mich., Aug. 14 CJPS Enterprises, LLC, ... today that it,has put online more resources for ... market, or to grow their existing healthcare,business. Those ... This project is dedicated to providing users ...
Cached Biology Technology:Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 2Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 3Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 4Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 5Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 6Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 7Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 8Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 9CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3The Michigan Life Sciences Pipeline Adds More Resources On Its Website 2
(Date:4/18/2014)... NC Seeds that sprout as soon as they,re planted ... need to be more careful. In the wild, a plant ... day would risk disaster. More than just an insurance policy ... that seed dormancy has long-term advantages too: Plants whose ... rise to more species, finds in a team of researchers ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... bio-based plastic packaging is not only eco-friendly but also ... The plastic packaging industry is moving towards completely bio-based ... the production of plastics equates to approximately five per ... per cent of all plastics are used in packaging, ...
... well-known fairy tale, Rumpelstiltskin used magic to weave straw into ... to turn straw (and other forms of biomass) into today,s ... in which minute particles of gold dot the surface of ... two materials are strong enough to breaks the O-O bond ...
... Software Inc. of Ottawa, Canada announced today it ... lead its company awareness and lead generation campaigns. ... in developing integrated marketing programs that target embedded ... messaging and positioning, PR, content development, partner co-marketing ...
Cached Biology News:Plastic packaging industry is moving towards completely bio-based products 2Gases from grasses 2Gases from grasses 3Crank Software Selects TREW Marketing for Embedded Industry Outreach 2Crank Software Selects TREW Marketing for Embedded Industry Outreach 3
... Rabbits x 2 , Maintenance ... x1 /each , Immunizations/Boost injections ... 5 ml) x1 /each , Production ... , Final Bleed ~ 100 ml blood (~50 ...
... 500 g protein in 200 l SDS-PAGE ... cell lysate; Abelson transformed macrophage cells, ... positive control, should be stored ... be minimized, sample vial should ...
muscle actin (HUC1-1)...
...
Biology Products: